ALK Abello Posts 18% Revenue Growth in Q1 2026, Upgrades Full-Year Outlook
Event summary
- ALK Abello reported 18% organic revenue growth in Q1 2026, with tablet sales up 18% driven by Europe and North America.
- Operating profit (EBIT) increased by 22% to DKK 570 million, with an EBIT margin of 32%.
- Free cash flow doubled to DKK 671 million, driven by higher earnings and changes in working capital.
- The full-year outlook was upgraded, with revenue growth now expected at 13-16% (previously 11-15%) and EBIT margin at around 26% (previously 25%).
- Phase 2 trial for peanut allergy tablet successful, progressing to phase 3 expected to be initiated in late 2026.
The big picture
ALK Abello’s strong Q1 2026 performance reflects its strategic focus on expanding patient access and operational excellence in the specialty allergy market. The company’s ability to drive double-digit growth across key regions and product lines underscores its leadership position. The upgraded full-year outlook signals confidence in sustaining this momentum, despite potential challenges in international markets and the need for continued innovation in its product pipeline.
What we're watching
- Execution Risk
- Whether ALK can sustain the momentum in tablet sales across Europe and North America while managing the phasing of shipments in international markets.
- Regulatory Dynamics
- The pace at which new approvals for neffy® nasal adrenaline spray will drive market expansion in Canada and the EU.
- Innovation Pipeline
- How the progression of the peanut allergy tablet to phase 3 trials will impact ALK’s long-term product portfolio and market positioning.
Related topics